1080 Tumor Treating Fields (TTFields) application induces a pro-inflammatory phenotype in macrophages
Main Authors: | Tal Kan, Moshe Giladi, Uri Weinberg, Yoram Palti, Yiftah Barsheshet, Boris Brant, Tali Voloshin, Alexandra Volodin, Lilach Koren, Anat Klein-Goldberg, Efrat Zemer-Tov, Rom Paz, Tharwat Haj Khalil, Bella Koltun, Adi Haber |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
726 Tumor Treating Fields (TTFields) induce an altered polarization program in M1/M2 macrophages
by: Moshe Giladi, et al.
Published: (2021-11-01) -
Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model
by: Yiftah Barsheshet, et al.
Published: (2022-11-01) -
Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Actin Dynamics
by: Tali Voloshin, et al.
Published: (2020-10-01) -
Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma <i>In Vitro</i> and <i>In Vivo</i>
by: Shiri Davidi, et al.
Published: (2022-06-01) -
Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma <i>In Vitro</i> and <i>In Vivo</i>. <i>Cancers</i> 2022, <i>14</i>, 2959
by: Shiri Davidi, et al.
Published: (2023-02-01)